# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frida Kahlo (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI011-SYN-TD
- Date: 1944-10-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Ortega, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week chronic pain follow-up on the day of the rehabilitation consultation. **S**

## History of present illness

Ms. Kahlo returns two weeks after her first visit, on the day of her physical medicine and rehabilitation consultation. The rehabilitation plan starts physical therapy twice a week with graded exercise, core and hip strengthening, and aquatic therapy, with a shoe lift for her shorter right leg; her first session is today. She has taken duloxetine 30 mg daily for two weeks. It caused mild nausea for the first few days, which has passed, and no dizziness, sweating, or sleep change. She takes acetaminophen 1 g three times a day and uses the diclofenac gel on her ankle, which makes standing easier. She still takes no more than four oxycodone tablets a day and has needed no early refills. The burning in her right leg is a little less at night. She can stand at the easel for about 15 minutes before the pain makes her sit. She has agreed to a first small reduction in her oxycodone dose at the four-week visit, provided her function holds, and asks that the taper stay slow. **S**

| Element | Detail |
|---|---|
| Rehabilitation | Consultation today; physical therapy twice weekly starts today; shoe lift prescribed |
| Duloxetine 30 mg | Two weeks; brief early nausea, now gone |
| Opioid use | No more than four oxycodone tablets a day; no early refills |
| Function | Stands at the easel for about 15 minutes |
| Taper | Agrees to a first small reduction at the four-week visit |
| PEG | 7.0, from 7.3 at intake |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No drowsiness, fever, or weight change |
| Gastrointestinal | Negative | Nausea gone; no constipation; bowel habit unchanged |
| Musculoskeletal | Positive | Constant low back and pelvic pain; right ankle pain on standing; no falls |
| Neurological | Positive | Burning in the right leg, a little less at night; no new weakness or numbness; no bladder or bowel control change |
| Psychiatric | Positive | Frustrated at times by pain; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Oxycodone 10 mg oral tablet, one tablet every 6 hours as needed for pain, no more than four a day (60 MME a day) **S**
- Duloxetine 60 mg delayed-release oral capsule, one capsule daily **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily **S**
- Diclofenac sodium 1% topical gel, 2 g to the right ankle four times daily **S**
- Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet daily **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostril **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50 kg; BMI 19.5 kg/m². All vital signs are synthetic.

PEG pain and function score (0-10): 7. All results are synthetic.

## Change since baseline

- PEG pain and function score (0-10): 7.3 at baseline, 7 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and talkative; not sedated; pupils equal and normal in size |
| Back | Lumbar paraspinal tenderness; healed lumbar surgical scars |
| Right ankle | Bony enlargement and reduced motion; no effusion; foot turned outward |
| Neurological | Right leg weakness and reduced reflexes, unchanged from intake |
| Gait | Walks with a cane and a limp from the shorter right leg |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic post-traumatic back and pelvic pain with right leg neuropathic features** (G89.21). PEG 7.0, slightly better than 7.3 at intake. Duloxetine 30 mg is tolerated after two weeks. **S**
   - Increase duloxetine to 60 mg daily.
   - Physical therapy twice weekly from today, with daily home exercises.
   - Referral for cognitive behavioral therapy for chronic pain.
   - Continue acetaminophen 1 g three times a day, no more than 3 g a day.
2. **Post-traumatic osteoarthritis of the right ankle and foot** (M19.171). Ankle pain limits standing; no effusion. The diclofenac gel helps. **S**
   - Continue diclofenac gel four times daily.
   - Ankle radiograph not repeated.
3. **Right leg weakness and shortening after childhood polio** (B91). Leg-length difference adds to back and ankle strain. **S**
   - Shoe lift prescribed by the rehabilitation team.
4. **Long-term opioid therapy, 60 MME a day** (Z79.891). No sedation, constipation, or falls. Single prescriber; naloxone at home. **S**
   - No change in the oxycodone dose today.
   - First reduction of about 10 percent at the four-week visit, as she agreed; it can be paused if pain or function worsens.
   - Keep the oxycodone in a locked box.
5. **Vitamin D deficiency** (E55.9). On cholecalciferol 2,000 units daily for two weeks. **S**
   - Recheck 25-hydroxyvitamin D about three months after starting.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PEG pain, enjoyment of life, and general activity score | Every visit | Completed today | 7.0, from 7.3 at intake |
| Survey | PHQ-9 depression score, with item 9 | Every 2 to 4 weeks during active treatment | Up to date | 8 at intake with item 9 scored 0; next at the four-week visit |
| Medication safety | Opioid benefits and harms: function, sedation, constipation, falls | Every visit during a taper; at least every 3 months | Completed today | No sedation, constipation, or falls; function slowly improving |
| Medication safety | Prescription drug monitoring program check | Before each opioid prescription; at least every 3 months | Up to date | Checked at intake: a single prescriber and no sedatives. No opioid prescription today |
| Laboratory | Urine drug test, with consent | Before long-term therapy, then at least annually | Up to date | At intake, consistent with the prescribed oxycodone only |
| Medication safety | Naloxone at home, with a family member trained | Offer when starting or continuing opioids; review each visit | Up to date | Dispensed at intake, with her spouse taught to use it |
| Medication safety | Concurrent benzodiazepines or other sedatives | Every visit | Completed today | None prescribed or taken |
| Medication safety | Duloxetine tolerance after starting | About 2 weeks after starting and after each dose change | Completed today | Brief nausea only; blood pressure 116/72. Increased to 60 mg |
| Laboratory | ALT on regular acetaminophen | Periodically when acetaminophen approaches 3 g a day | Up to date | 22 U/L at intake; recheck at the six-week review |
| Laboratory | CBC, creatinine, and blood pressure for chronic oral NSAID use | Every 6 to 12 months on oral NSAIDs | Not indicated | Topical diclofenac only; creatinine 0.72 at intake |
| Examination | Right ankle examination: range of motion, effusion, alignment | Every visit | Completed today | Bony enlargement and reduced motion; no effusion |
| Imaging | Right ankle radiograph | Only for diagnostic uncertainty, clinical change, or surgical planning | Not indicated | Done at intake; no routine surveillance imaging |
| Referral | Physical medicine and rehabilitation | Once, for a multimodal rehabilitation plan | Completed today | Seen today; physical therapy and a shoe lift |
| Referral | Cognitive behavioral therapy for chronic pain | Early in a multimodal plan | Referred | Referred today |
| Self-management | Exercise program adherence | Every visit | Completed today | Physical therapy twice weekly starts today, with home exercises |
| Laboratory | 25-hydroxyvitamin D | About 3 months after starting repletion | Due | 18 ng/mL at intake; recheck in about eleven weeks |

## Goal progress

- Improve the PEG score by at least 30% from baseline. In progress; target 1944-10-29. **S**
- Stand at the easel for 30 minutes at a time by the six-week review. In progress; target 1944-10-29. **S**
- First opioid dose reduction, agreed by the patient, without loss of function. In progress; target 1944-10-29. **S**
- Naloxone in the home with a family member trained to use it. Outcome by 1944-09-17: Naloxone nasal spray dispensed; spouse taught at the first visit. **S**

## Medication changes

- Stopped: Duloxetine 30 mg delayed-release oral capsule, one capsule daily **S**
- Started: Duloxetine 60 mg delayed-release oral capsule, one capsule daily **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017), American College of Physicians (Annals of Internal Medicine)
- VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022), U.S. Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026), Aether Forge

## Follow-up

- Physical therapy twice weekly. Four-week chronic pain follow-up in two weeks for the first oxycodone reduction. **S**
- Next scheduled visit 1944-10-15: four-week chronic pain follow-up with the first opioid dose reduction. **S**
